Nurse Practitioner and Hello Dose Founder Bracha Banayan, RN, FNP, Releases "Why Are You Still Hungry?" -- A Patient Guide to GLP-1 Medications and Lasting Habit Change

Written for anyone taking a GLP-1 medication, considering one, or stuck in cycles of weight gain and food noise, the new book challenges the idea that weight struggles are a failure of willpower. Banayan draws on her clinical practice and her own experience with GLP-1 therapy to offer a practical roadmap for using these medications responsibly and making lifestyle changes that stick.

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Bracha Banayan, RN, FNP, founder of telehealth practice Hello Dose, today released her new book, "Why Are You Still Hungry?" The paperback is available through Amazon, Barnes & Noble and BookBaby, and the eBook is available through Apple Books, Barnes & Noble, Kobo and BookBaby's Bookshop.

Banayan walks readers through the biological factors that can make weight management so challenging, including insulin resistance, the body's set point and "food noise," the persistent, intrusive thoughts about food that many people describe. She explains in plain language how GLP-1 and GIP receptor agonist medications, such as semaglutide and tirzepatide, act on both the gut and the brain.

Rather than presenting medication as a shortcut, the book frames GLP-1 therapy as one tool that works best alongside behavior change. Banayan introduces her DROP™ Method, a four-part framework built around Dosing, Real-time feedback, Owning your habits and the Pause factor. She also covers side-effect management, working with a provider on appropriate dosing, and the stigma and shame that often surround weight-loss medications. Later chapters explore the psychological and emotional side of healing one's relationship with food.

Banayan came to the subject as a skeptic. She once gave patients the familiar advice to eat less and move more, until she gained roughly 20 pounds during the COVID-19 pandemic and spent nearly two years unable to lose it through diet and exercise alone. She eventually tried semaglutide under appropriate medical care, and the experience reshaped how she practices. At the same time, she was seeing widespread confusion among patients, from people taking higher doses than they needed to people starting treatment without addressing the habits underneath.

The book carries an endorsement from Amy Shecter, former CEO of CorePower Yoga and Glamsquad, who credits it with bringing clarity to the science behind GLP-1s and giving patients a practical roadmap in a space crowded with misinformation.

"So many people have been made to feel that their weight is a character flaw, and it isn't. It's biology, and asking for help takes courage," said Banayan. "But these medications aren't magic, either. They open a window, and what you do with that window matters. I wrote this book to give people a clear roadmap for working with their provider, rewiring their habits and building a healthy life that lasts well beyond the prescription."

The book is intended for educational purposes and does not replace individualized medical advice, diagnosis or treatment. GLP-1 receptor agonists are FDA-approved prescription medications for specific medical indications, should be used only under the supervision of a licensed healthcare provider, and are not appropriate for everyone. Individual results vary.

More About Bracha Banayan and Hello Dose

Bracha Banayan, RN, FNP, is a board-certified Family Nurse Practitioner and healthcare entrepreneur based in New York City. She is the founder and CEO of Hello Dose and IVDrips, and brings more than a decade of clinical experience in emergency medicine and infusion therapy. Banayan has drawn on her clinical GLP-1 experience with more than 1,000 patients and has been featured on CBS News and in The Wall Street Journal. She personally trains and selects the Nurse Practitioners who care for Hello Dose patients.

Hello Dose is a clinician-led telehealth medical weight management practice offering personalized, medically supervised programs that may incorporate GLP-1 therapy, clinical monitoring, behavioral and lifestyle guidance and ongoing patient education, based on individual needs and clinical appropriateness. Hello Dose offers telehealth services to eligible patients nationwide, subject to provider availability and applicable state regulations. For more information, please visit www.hellodose.com.

Media Contact
Bracha Banayan, RN, FNP
Hello Dose
(607) 638-3948
https://www.hellodose.com

SOURCE Hello Dose.